During a panel discussion at the National Society of Genetic Counselors meeting, genetic counselors discuss the risks and benefits of gene therapies.

The European Commission approval was based on two Phase III trials showing Vyloy plus chemo improved survival outcomes versus chemo alone.

Despite showing a progression-free survival benefit, the antibody-drug conjugate did not improve overall survival in HR-positive, HER2-negative or -low breast cancer.

NEW YORK – Sensorion on Monday said that by year end it expects to complete dosing the first cohort of pediatric patients with congenital hearing loss with its gene therapy candidate SENS-501 in the ...

Researchers reported at the ESMO Congress that 78 percent of patients responded to front-line treatment with Lumakras, ...

At a thrombosis research center, an observational study is underway investigating the impact of numerous biomarkers on ...

Researchers at the ESMO Congress presented data showing better responses on dual-checkpoint blockade in the biomarker-defined ...

If it can secure the funds, Oncolytics will advance the agent into a pivotal study, based on positive data from the Phase I BRACELET-1 trial.

A group of hospital systems are using the machine-learning model to guide decisions on who should be tested for high levels of lipoprotein(a).

The agency reviewed data from the MARIPOSA-2 trial and approved the regimen for patients with common EGFR mutations who are progressing on EGFR inhibitors.

Researchers explored HER2 testing discordance, biomarkers of response, patient-reported outcomes, and the risk of lung-related disease.

Within the registrational trial, investigators will compare a single dose of 4D-150 to treatment with standard anti-VEGF therapy.